[go: up one dir, main page]

AU2289799A - Vaccine composition comprising milled lyophilisate of antigenic whole cells - Google Patents

Vaccine composition comprising milled lyophilisate of antigenic whole cells

Info

Publication number
AU2289799A
AU2289799A AU22897/99A AU2289799A AU2289799A AU 2289799 A AU2289799 A AU 2289799A AU 22897/99 A AU22897/99 A AU 22897/99A AU 2289799 A AU2289799 A AU 2289799A AU 2289799 A AU2289799 A AU 2289799A
Authority
AU
Australia
Prior art keywords
lyophilisate
milled
vaccine composition
whole cells
antigenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22897/99A
Other languages
English (en)
Inventor
Roderick Peter Hafner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Provalis UK Ltd
Original Assignee
RABY Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RABY Ltd filed Critical RABY Ltd
Publication of AU2289799A publication Critical patent/AU2289799A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU22897/99A 1998-01-28 1999-01-28 Vaccine composition comprising milled lyophilisate of antigenic whole cells Abandoned AU2289799A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9801870.8A GB9801870D0 (en) 1998-01-28 1998-01-28 Vaccine composition
GB9801870 1998-01-28
PCT/GB1999/000287 WO1999038529A1 (fr) 1998-01-28 1999-01-28 Composition vaccinale comprenant un lyophilisat de cellules entieres antigeniques usinees

Publications (1)

Publication Number Publication Date
AU2289799A true AU2289799A (en) 1999-08-16

Family

ID=10826079

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22897/99A Abandoned AU2289799A (en) 1998-01-28 1999-01-28 Vaccine composition comprising milled lyophilisate of antigenic whole cells

Country Status (3)

Country Link
AU (1) AU2289799A (fr)
GB (1) GB9801870D0 (fr)
WO (1) WO1999038529A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020009429A1 (en) * 1999-01-29 2002-01-24 Galagen, Inc. Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
LT1212045T (lt) 1999-08-24 2016-12-12 Abic Biological Laboratories Ltd. Vakcinos kompozicija ir jos panaudojimas
US6592869B2 (en) 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
US7914799B2 (en) * 2001-08-27 2011-03-29 Immunitor USA, Inc. Anti-fungal composition
CN1602199B (zh) * 2001-12-11 2012-04-04 巴斯德研究院 用于治疗包含免疫失调的疾病的革兰氏阳性菌制剂
EP1838329B1 (fr) 2004-08-17 2011-10-05 Hunter Immunology Limited Procédé de production de vaccins inactives oraux
DE102004046391A1 (de) * 2004-09-24 2006-04-06 Bioveta Ag Neuer Impfstoff für veterinäre und humanmedizinische Prophylaxe und Therapie

Also Published As

Publication number Publication date
WO1999038529A1 (fr) 1999-08-05
GB9801870D0 (en) 1998-03-25

Similar Documents

Publication Publication Date Title
AU2903999A (en) Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
AU2230199A (en) Vaccine compositions and methods of modulating immune responses
AU3913800A (en) Novel antioxidant formulations and methods for using them
AU5612686A (en) Aids antigen, diagnosis and immunogenic compositions
AUPP968699A0 (en) Therapeutic compositions and method for their preparation
AUPP589398A0 (en) Immunogenic compositions and uses thereof
AU1947399A (en) Opalescent cosmetic compositions and methods for their preparation
AU2289799A (en) Vaccine composition comprising milled lyophilisate of antigenic whole cells
AU2001241159A1 (en) Silicone gel composition
AU2001295672A1 (en) Vaccine composition and stabilisation method
AU5608798A (en) Formulations of recombinant papillomavirus vaccines
AU7308200A (en) Novel hev antigenic peptide and methods
AU5744800A (en) Vaccine formulations and methods for immunizing an individual against shed antigen-specific b cells
AU4450696A (en) Enhanced immunogenic vaccine
AU2901997A (en) Immunogenic complex, use, method of preparation thereof and vaccine containing same
AU3552797A (en) Vaccine preparations
AU3755999A (en) Proteins that direct the secretion of virulence proteins and vaccines comprisingthem
AU2738000A (en) Oral hygiene preparations; associated methods and kit
AU4774200A (en) Long term cell culture of human carcinoma
AU9588398A (en) Vaccine compositions and methods of enhancing vaccine efficacy
AU4839100A (en) Methods of using and compositions comprising n-desmethylzolpidem
AU2001241060A1 (en) Gel preparations for oral administration having improved preservation properties
AU3452997A (en) Vaccine compositions
AU1848801A (en) Formulation containing peanut leaf extract and its preparation
AU8513698A (en) Methods and compositions for designing vaccines

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase